VER
Vascular & Endovascular Review

Detection of Neurological diseases Using Machine Learning

Deep Narayan[1], Dr Ranjan Kumar Mishra[1*], Dr Pramod Kumar Singh[1], Shashwat Raj[1], Bibhuti Kumbhakar[1], Sonu kumar[1], Dr Pratik Patel[2], Dr Sudhir Dawra[2]

[1]Department of Information Technology, Netaji Subhas University, Jamshedpur,Jharkhand,India.
[2]Department of School of Forensic Science - National Forensic Sciences University, Gandhinagar Gujarat.
[3]Department of Computer Science and Engineering - SRM Institute of Science and Technology, Modinagar, Uttar Pradesh.

***Corresponding author: Dr. Ranjan Kumar Mishra,**
Email ID: ranjanlnmi4u@gmail.com

ABSTRACT

The human pupil serves not only as a conduit for visual information but also as a delicate physiological indicator that mirrors the internal condition of the brain and the autonomic nervous system. The dynamics of the pupil particularly variations in size, the speed of constriction and dilation, and the latency of response are governed by intricate neural circuits that encompass both sympathetic and parasympathetic pathways. These reactions can be initiated by external stimuli (like light) as well as internal cognitive activities (including attention, memory, and emotional arousal). Recent developments in neuroscience have shown that irregularities in these dynamic pupil behaviors can act as early indicators of neurological and psychiatric conditions, such as Alzheimer's disease, Parkinson's disease, Autism Spectrum Disorder (ASD), Multiple Sclerosis, and Traumatic Brain Injury (TBI). A slow pupil light reflex or less pupil dilation during mental tasks has been linked to neurodegeneration and cognitive decline. As a result, non-invasive pupillometry may assist in the early diagnosis, tracking of disease progression, and evaluation of treatment effectiveness. At the same time, the domain of machine learning (ML) has transformed biomedical research by facilitating the detection of complex patterns within high-dimensional time-series data. Machine learning algorithms excel in modeling the intricate, nonlinear dynamics that define pupil behavior. By integrating machine learning techniques with pupillometry, we can develop automated, scalable systems that are able to detect early signs of neurological impairment through subtle changes in eye physiology. This study conducted to investigate the application of pupil dynamics as digital biomarkers through the recording and analysis of pupil reactions to light and cognitive stimuli. The research will concentrate on deriving significant features from pupil time-series data and developing machine learning models to differentiate between healthy individuals and those with neurological impairments. Additionally, it will assess the reliability and interpretability of these models in both clinical and real-world environments. By integrating knowledge from neuroscience, computer vision, and machine learning, this study aims to provide an innovative, affordable solution for early neurological screening ultimately facilitating prompt diagnosis and tailored treatment strategies.

KEYWORDS: Machine Learning, Autism Spectrum Disorder, Traumatic Brain Injury, positron emission tomography.

How to Cite: Deep Narayan, Ranjan Kumar Mishra, Pramod Kumar Singh, Shashwat Raj, Bibhuti Kumbhakar, Sonu kumar, Pratik Patel, Sudhir Dawra, (2024) Detection of Neurological diseases Using Machine Learning, Vascular and Endovascular Review, Vol.7, No.2, 77-87

INTRODUCTION

Neurological diseases represent one of the most considerable challenges to global health, affecting millions and imposing a significant socio-economic burden. Conditions like Alzheimer's disease, Parkinson's disease, epilepsy, stroke, and multiple sclerosis not only hinder motor and cognitive functions but also lead to long-term disabilities and dependence on others. The World Health Organization (WHO) indicates that neurological disorders make up more than 6% of the global disease burden, a figure expected to rise notably as population's age. Prompt and accurate diagnosis of these conditions is crucial for effective treatment, improved prognosis, and enhanced quality of life. However, conventional diagnostic approaches largely rely on clinical assessments, neuroimaging evaluations, and laboratory tests, which can be subjective, time-consuming, and dependent on clinician expertise. This situation has generated a need for objective, data-driven, and scalable diagnostic solutions, leading to the exploration of artificial intelligence (AI) and machine learning (ML) for identifying neurological diseases.[1-3].

Machine learning, a branch of artificial intelligence, is dedicated to creating algorithms that can learn from data and make predictions or decisions without the need for explicit programming. In the realm of neurological disorders, machine learning presents the opportunity to automatically analyze intricate biomedical datasets such as magnetic resonance imaging (MRI), electroencephalogram (EEG), and positron emission tomography (PET) scans to pinpoint disease-specific biomarkers. In contrast to conventional statistical techniques, machine learning algorithms are capable of capturing non-linear relationships and subtle patterns within high-dimensional data, which facilitates more precise disease classification and prognosis forecasting. Additionally, progress in deep learning, especially through convolutional neural networks (CNNs) and recurrent neural networks (RNNs), has transformed the analysis of medical images and signals, showcasing outstanding performance in identifying neurological abnormalities. Recent studies have demonstrated encouraging outcomes in the application of machine learning techniques across various neurological fields. For example, models based on convolutional neural networks (CNNs) have reached high levels of accuracy in identifying Alzheimer's disease through the analysis of structural MRI scans, pinpointing cortical atrophy and hippocampal shrinkage as early warning signs.[4-9]. In a similar vein, research on Parkinson's disease has utilized machine learning algorithms to examine motor activity patterns, speech characteristics, and neuroimaging data, enabling the distinction between healthy individuals and those with the disease.

Moreover, EEG-based machine learning models have proven effective in diagnosing epilepsy by detecting specific seizure patterns within brain signals. These instances underscore the transformative capabilities of machine learning in improving diagnostic accuracy and assisting healthcare professionals in their decision-making processes. Despite these advancements, numerous challenges persist. Neurological data frequently exhibit heterogeneity, noise, and limited size, which can impede model generalization. The opaque nature of deep learning models raises issues regarding interpretability and clinical trust. Moreover, data privacy and ethical considerations in managing sensitive patient information continue to pose significant challenges. As a result, current research is increasingly directed towards explainable AI (XAI) frameworks, transfer learning, and federated learning to enhance transparency, robustness, and scalability in medical applications. The incorporation of machine learning (ML) in the detection of neurological diseases not only improves diagnostic precision but also enables early intervention, customized treatment strategies, and ongoing patient surveillance. By utilizing multimodal datasets such as imaging, electrophysiological, genetic, and behavioral information ML models can reveal intricate interactions that contribute to neurological disorders. This interdisciplinary strategy is in line with the evolving concept of precision medicine, where data-centric technologies are used to customize healthcare solutions for each patient.[10-13].

In this research, we explore the application of machine learning methods in identifying and categorizing neurological disorders through various biomedical datasets. The objective of this paper is to deliver a thorough summary of current ML algorithms, feature extraction techniques, and performance evaluation metrics pertinent to neurological diagnostics. Furthermore, we assess the efficacy of conventional machine learning models against deep learning frameworks in recognizing disease-specific patterns. The primary aim of this study is to aid in the creation of an intelligent, automated, and dependable system for the early detection of neurological diseases, thus assisting clinicians in making timely diagnoses and enhancing patient outcomes.

1.1 Limitations of conventional diagnostic methods

The assessment of neurological disorders has traditionally depended on clinical evaluations, neuroimaging methods, and laboratory tests. Although these approaches have greatly enhanced medical knowledge, they possess several drawbacks that impede the early and precise identification of diseases. Clinical evaluations often rely significantly on a physician's expertise, observational abilities, and subjective interpretation of symptoms, which can differ among doctors. Neurological conditions such as Alzheimer's and Parkinson's disease frequently exhibit overlapping clinical signs, complicating differential diagnosis, especially in the initial stages. Neuroimaging methods like Magnetic Resonance Imaging (MRI), Computed Tomography (CT), and Positron Emission Tomography (PET) scans offer important structural and functional information about the brain. Nevertheless, their interpretation necessitates expert radiological evaluation, which is susceptible to human error and variability between observers. Additionally, subtle changes in the early stages of disease may go unnoticed through visual examination alone. While Electroencephalogram (EEG) analysis is beneficial for conditions like epilepsy, it is constrained by signal noise, variability among patients, and the difficulty of manually identifying disease-specific patterns. Moreover, traditional diagnostic methods tend to be lengthy, costly, and invasive, which creates challenges for both healthcare systems and patients. The availability of advanced imaging technology and skilled neurologists is restricted, particularly in developing areas. These limitations hinder timely diagnosis and treatment, thereby diminishing the likelihood of effective intervention. As a result, there is an urgent requirement for automated, data-centric diagnostic solutions like machine learning that can objectively evaluate intricate datasets, improve diagnostic accuracy, and support clinicians in early detection and decision-making.[14].

1.2 Emergence of Artificial Intelligence (AI) and Machine Learning (ML) in medicine

In recent years, Artificial Intelligence (AI) and Machine Learning (ML) have become transformative forces in contemporary medicine, providing innovative solutions to persistent challenges in diagnosis, prognosis, and treatment planning. AI is defined as computational systems created to mimic human intelligence, whereas ML is a branch of AI that allows computers to learn from large datasets and make predictions without the need for explicit programming. These technologies have demonstrated remarkable potential in analyzing intricate biomedical data, uncovering subtle patterns, and delivering data-driven insights that exceed human analytical abilities. In the realm of neurology, AI and ML have facilitated considerable advancements in the automated analysis of medical images, electrophysiological signals, and clinical records. Algorithms like Support Vector Machines (SVM), Random Forests (RF), and Convolutional Neural Networks (CNNs) have been effectively utilized to identify early biomarkers of neurological disorders, categorize patient conditions, and forecast disease progression. For instance, ML models can analyze MRI or EEG data to detect minute structural or functional irregularities that might be overlooked during visual examination. Furthermore, AI-powered diagnostic systems improve precision medicine by customizing treatment plans to fit individual patient profiles, which leads to better therapeutic results. They also shorten diagnostic times, assist doctors in making clinical decisions, and enhance accessibility in resource-constrained environments via telemedicine and cloud-based analytics. As computational capabilities and data availability grow, AI and machine learning are anticipated to become even more crucial in transforming healthcare, especially in the early identification and management of neurological disorders.[15].

1.3 Conventional Diagnostic Techniques

Traditional diagnostic methods for neurological disorders primarily depend on clinical evaluations, neuroimaging, and electrophysiological tests to detect structural or functional irregularities in the nervous system. Neurologists usually start with comprehensive patient histories and neurological examinations, which include assessments of reflexes, motor abilities, coordination, sensory functions, and cognitive skills. Although these evaluations are valuable, they heavily rely on the clinician's knowledge and subjective judgment, potentially resulting in diagnostic inconsistencies. Neuroimaging techniques like Magnetic Resonance Imaging (MRI), Computed Tomography (CT), and Positron Emission Tomography (PET) have become essential in identifying brain lesions, tumors, ischemic strokes, and neurodegenerative alterations. MRI offers high-resolution structural information, while PET and functional MRI (fMRI) provide insights into metabolic and functional brain activities. Nonetheless, these imaging techniques are resource-demanding and may not always capture subtle changes during the early stages of disease. Electroencephalography (EEG) and electromyography (EMG) are extensively utilized for the functional assessment of neural activity, especially in conditions such as epilepsy and neuropathies. EEG captures electrical signals from the brain to detect abnormal wave patterns that may indicate seizures or other disorders. Although they hold significant clinical importance, the interpretation of EEG and EMG data is intricate and labor-intensive, necessitating expert evaluation to distinguish pathological signals from normal variations or artifacts. These challenges underscore the increasing demand for automated, data-driven solutions—like machine learning models to facilitate the early, objective, and dependable identification of neurological disorders.[16-19].

1.4 Previous Research Studies

An increasing amount of research has investigated the use of machine learning (ML) and artificial intelligence (AI) for the detection and classification of neurological disorders, highlighting their ability to improve diagnostic precision and lessen the burden on clinicians. Several investigations have concentrated on the identification of Alzheimer’s disease (AD) through neuroimaging data. For example, convolutional neural networks (CNNs) that are trained on MRI datasets have effectively differentiated between healthy subjects, patients with mild cognitive impairment (MCI), and those with AD, achieving accuracies greater than 90%. Likewise, support vector machines (SVM) and random forest algorithms have been utilized to examine both structural and functional brain imaging characteristics, pinpointing disease-specific biomarkers such as hippocampal atrophy and cortical thinning. In the realm of Parkinson’s disease research, ML models have been created to evaluate motor symptoms, changes in voice, and abnormalities in gait. Research employing deep learning-based image recognition alongside wearable sensor data has demonstrated excellent diagnostic capabilities in distinguishing Parkinson’s patients from healthy individuals. In the case of epilepsy, algorithms trained on EEG recordings have shown effectiveness in identifying and forecasting seizure occurrences, offering essential tools for ongoing patient surveillance. Recent research emphasizes the incorporation of multimodal data such as neuroimaging, genomic, and clinical factors to enhance the robustness and interpretability of models. However, challenges remain, including data heterogeneity, limited sample sizes, and the absence of explain ability in intricate models. Still, the overall findings highlight the transformative potential of machine learning-based methods in improving neurological diagnostics and facilitating the transition to precision medicine.[20-22].

1.5 Data Acquisition and Preprocessing

Data acquisition and preprocessing are fundamental components of any machine learning (ML) framework designed for the detection of neurological diseases. To train precise predictive models, it is crucial to have reliable and representative data. In the field of neurological research, data is generally sourced from various channels, including magnetic resonance imaging (MRI), computed tomography (CT), electroencephalography (EEG), positron emission tomography (PET), as well as clinical or genetic databases. These datasets often encompass both structural and functional details, allowing for a thorough examination of the brain's structure and function. Publicly accessible repositories, like the Alzheimer’s disease Neuroimaging Initiative (ADNI) and the Parkinson’s Progression Markers Initiative (PPMI), are commonly utilized to facilitate model development and validation. Preprocessing plays a vital role in enhancing data quality and ensuring consistency among samples. For imaging data, preprocessing tasks include normalization, skull stripping, motion correction, and intensity standardization to remove artifacts and improve image clarity. In the case of EEG or signal-based data, preprocessing involves noise filtering, signal segmentation, and feature extraction to identify significant patterns linked to neurological activity. Clinical datasets may necessitate the management of missing values, categorical encoding, and normalization to ensure consistent feature scaling. Furthermore, methods like data augmentation and dimensionality reduction (for instance, Principal Component Analysis) are utilized to tackle dataset imbalance and decrease computational complexity. Effective data pre-processing not only improves model performance but also reduces over fitting, thereby ensuring the model generalizes well to new data. Therefore, a well-organized data acquisition and preprocessing pipeline is crucial for developing robust, interpretable, and clinically relevant machine learning-based diagnostic systems for neurological disorders.[23].

1.6 Feature Extraction and Selection

Feature extraction and selection are essential steps in creating effective and precise machine learning (ML) models for the detection of neurological diseases. The main goal of feature extraction is to obtain significant and distinguishing information from raw data—such as medical images, EEG signals, or clinical parameters—that can accurately reflect the characteristics of the underlying disease. In neuroimaging, the features extracted may consist of volumetric measurements of brain regions, texture patterns, cortical thickness, or gray matter density. For studies based on EEG, statistical and spectral features like wavelet coefficients, entropy, and frequency band power are frequently utilized to capture variations in brain activity linked to neurological disorders [24]. On the other hand, feature selection aims to pinpoint the most pertinent subset of features that significantly enhance the model’s predictive capabilities. High-dimensional medical datasets often include redundant or irrelevant attributes that can result in over fitting and heightened computational complexity. To tackle this issue, techniques such as Recursive Feature Elimination (RFE), mutual information, correlation analysis, and principal component analysis (PCA) are employed to refine the feature sets. These approaches contribute to improved model interpretability while preserving diagnostic accuracy. The integration of robust feature extraction with effective selection not only boosts classification performance but also assists in identifying potential biomarkers for early disease detection. Furthermore, feature selection facilitates explainable AI methodologies, enabling researchers and clinicians to gain a clearer understanding of which attributes are most closely linked to neurological conditions. Therefore, this phase is crucial in connecting raw biomedical data with dependable ML-based diagnostic models.[25].

1.6 Machine Learning Algorithms

Machine learning (ML) algorithms serve as the analytical foundation for automated systems that detect neurological diseases. These algorithms are crafted to identify patterns within intricate biomedical data, enabling them to make precise predictions or classifications. In the realm of neurological disorders, both conventional and advanced ML techniques have been extensively utilized, depending on the characteristics and volume of the data. Among the traditional algorithms, Support Vector Machines (SVM) are commonly employed due to their proficiency in managing high-dimensional datasets, which makes them particularly effective for classifying features derived from MRI or EEG. Random Forests (RF), which utilize ensemble learning, amalgamate several decision trees to enhance accuracy and reduce over fitting, providing excellent interpretability for analyzing feature importance. Additionally, k-Nearest Neighbors (k-NN) and Logistic Regression are utilized for smaller datasets or binary classifications, offering simplicity and computational efficiency.[26-29].

In recent years, deep learning models have surpassed traditional methods, especially in the analysis of image and signal data. Convolutional Neural Networks (CNNs) excel at extracting spatial features from brain imaging techniques, while Recurrent Neural Networks (RNNs) and Long Short-Term Memory (LSTM) architectures are well-suited for examining sequential EEG or time-series data. These models possess the capability to automatically learn hierarchical features, thus removing the necessity for manual extraction. Choosing the right algorithm is contingent upon the type and size of the dataset, as well as the level of interpretability required. The integration of multiple algorithms through hybrid or ensemble models has also demonstrated encouraging outcomes in enhancing diagnostic accuracy and generalization across various neurological conditions.[30].

1.7 Deep Learning Architectures

Deep learning (DL), a branch of machine learning, has transformed the detection of neurological diseases by facilitating automated feature learning from complex, high-dimensional biomedical data. Unlike conventional machine learning models that depend on manual feature engineering, deep learning architectures can autonomously recognize intricate patterns in neuroimaging, electrophysiological, and clinical datasets. The most prevalent DL models in this field include Convolutional Neural Networks (CNNs), Recurrent Neural Networks (RNNs), Autoencoders, and Deep Belief Networks (DBNs). Convolutional Neural Networks (CNNs) are especially effective for examining medical imaging techniques such as MRI, CT, and PET scans. They employ convolutional and pooling layers to capture spatial hierarchies and extract pertinent anatomical features, such as cortical thinning or hippocampal atrophy—critical indicators of conditions like Alzheimer's and Parkinson's. Recurrent Neural Networks (RNNs) and their advanced variant, Long Short-Term Memory (LSTM) networks, are particularly adept at handling sequential data such as EEG signals, facilitating temporal pattern recognition essential for epilepsy detection or sleep disorder evaluation.[31-34]. Auto encoders are utilized for unsupervised representation learning, data compression, and anomaly detection, frequently applied in recognizing early neurodegenerative changes. Likewise, Deep Belief Networks (DBNs) combine multiple hidden layers to learn hierarchical feature representations that enhance the accuracy of disease classification.[33].

1.8 Model Performance and Accuracy Metrics

Assessing the performance of machine learning (ML) models is an essential process for evaluating their reliability and effectiveness in detecting neurological diseases. A thorough evaluation guarantees that models not only reach high accuracy but also generalize effectively to new data, thereby minimizing the chances of incorrect diagnoses. Common performance metrics utilized in medical classification tasks encompass accuracy, precision, recall (sensitivity), specificity, F1-score, and the Area under the Receiver Operating Characteristic Curve (AUC-ROC). Accuracy indicates the overall percentage of correctly classified samples; however, it can be deceptive in imbalanced datasets where the prevalence of disease is low. Consequently, precision (the ratio of correctly identified positive cases to all predicted positives) and recall (the ratio of actual positive cases that are correctly identified) are vital for evaluating diagnostic effectiveness. The F1-score, which is the harmonic mean of precision and recall, offers a balanced assessment when both metrics are significant. Specificity measures the model's capability to accurately identify healthy individuals, thereby reducing false positives—a crucial factor in clinical environments.[35]. The AUC-ROC curve further demonstrates the balance between sensitivity and specificity, providing a detailed perspective on a model's discriminative ability. Moreover, confusion matrices are commonly employed to visualize true positives, false positives, false negatives, and true negatives, aiding in the identification of potential biases or shortcomings in classification performance.[34].

Table: 1 Common Types of Neurological Disorders

Category	**Examples**	**Primary Impact**
Neurodegenerative	Alzheimer's, Parkinson's, MS	Memory, movement, coordination

Neuromuscular	ALS, Muscular Dystrophy	Muscle control, strength
Brain Disorders	Epilepsy, Stroke, Migraines	Seizures, pain, motor and cognitive issues
Spinal Cord Disorders	Spina Bifida, SMA	Mobility, sensation

Table 2: Common Neurological Disorders

Disorder	**Key Symptoms**	**Notes**
Alzheimer's Disease	Memory loss, confusion, mood changes	Leading cause of dementia in older adults
Parkinson's Disease	Tremors, stiffness, slow movement	Caused by dopamine deficiency in the brain
Epilepsy	Seizures, loss of consciousness	Can be genetic or triggered by brain injury
Stroke	Sudden weakness, speech issues, paralysis	Caused by blocked or ruptured blood vessels

1.9 Challenges and Symptom Variability in Neurological Disorders

Neurological diseases present a unique diagnostic challenge due to their complex, overlapping, and often subtle symptomatology. Unlike conditions with clear biomarkers or visible pathology, many neurological disorders manifest through behavioral, cognitive, or motor changes that evolve over time and vary widely between individuals. A neurological disorder often present with overlapping symptoms, which makes distinguishing between conditions a significant challenge. Signs such as tremors, memory loss, fatigue, and speech difficulties can occur in multiple diseases, including Parkinson's, Alzheimer's, and multiple sclerosis. The situation is further complicated when psychiatric comorbidities such as depression or anxiety coexist, as these can blur the clinical picture and make diagnosis even more difficult. Adding to this complexity is the variability in how different disorders progress. [25]. Alzheimer's disease, for instance, typically advances slowly over many years, while stroke presents suddenly and with acute changes. Even within a single condition, individual differences in the timing, severity, and progression of symptoms make it difficult to rely on standardized diagnostic criteria. Traditional diagnostic tools also pose limitations. Although imaging techniques like MRI and CT scans are widely used, they often fail to identify early-stage disease. Similarly, EEG and EMG results can be difficult to interpret and require specialized expertise. Clinical assessments add another layer of complexity, since they depend heavily on subjective patient reports and the judgment of the physician. [27].

A further obstacle in diagnosis is the lack of reliable biomarkers. While genetic markers are available for certain diseases such as Huntington's, there are no broadly applicable or consistently validated biomarkers for early detection across neurological disorders. This gap contributes to delays in reaching a definitive diagnosis. Many patients undergo long diagnostic processes, often facing misdiagnoses or delayed specialist referrals, partly because early symptoms are dismissed as normal aging, psychological stress, or minor health issues. Demographic and environmental factors also play a critical role in how these conditions manifest and are diagnosed. Age, gender, ethnicity, and environmental exposures can significantly influence both the expression of symptoms and the overall risk of developing a neurological condition. In addition, cultural differences in how symptoms are perceived and reported can lead to underdiagnosed in certain populations, further limiting timely and accurate medical intervention. [13]. Machine learning algorithms have revolutionized neurological diagnostics by their ability to recognize intricate patterns within large, complex medical datasets. These sophisticated systems excel at analyzing diverse data types including brain imaging from MRI and CT scans, electrophysiological signals captured through EEG, genomic information, and comprehensive patient records. The complexity of neurological data often contains subtle patterns that exceed human interpretive capabilities, making machine learning an invaluable diagnostic partner. In brain imaging applications, machine learning models demonstrate remarkable proficiency in detecting early disease markers. For conditions like Alzheimer's disease and multiple sclerosis, these algorithms can analyze MRI and PET scans to identify regional brain changes and biomarkers that signal disease onset well before clinical symptoms manifest.[17]. Similarly, in electroencephalography analysis, machine learning algorithms excel at interpreting EEG patterns to detect abnormal brainwave activity in conditions such as epilepsy and Parkinson's disease, often successfully predicting seizures and other neurophysiological events before they occur. The power of machine learning truly shines in early detection and diagnosis, where it can identify subtle brain changes that might escape human observation. This capability is particularly crucial for neurological diseases like Alzheimer's, where early intervention significantly impacts patient outcomes. Machine learning models can analyze structural brain changes through MRI scans and predict the likelihood of developing Alzheimer's years before cognitive decline becomes apparent. These deep learning systems are trained to recognize early signs of amyloid plaques and tau tangles, the hallmark features of the disease.[21]. For Parkinson's disease, machine learning techniques including support vector machines and neural networks can detect subtle motor impairments through voice analysis, movement pattern assessment, and even pupillary response data, enabling earlier and more accurate diagnosis.[23].

Predicting disease progression represents another critical application where machine learning algorithms analyze longitudinal patient data to forecast how neurological conditions will evolve over time. By examining patterns in symptom changes, cognitive function decline, and imaging data evolution, these models identify risk factors for rapid disease progression, enabling clinicians to develop personalized treatment strategies. In multiple sclerosis, machine learning models utilize MRI scan data to predict disease progression, directly informing therapeutic decisions and intervention effectiveness assessments. For stroke recovery, these techniques track patient rehabilitation by analyzing movement recovery data from physical therapy sessions combined with brain scan information, helping predict long-term outcomes and guide rehabilitation approaches. Risk stratification and personalized treatment development represent significant contributions of machine learning in neurological medicine. These systems identify specific risk factors and patterns within patient data, empowering physicians to make more informed treatment decisions. Machine learning can analyze genetic data to identify mutations and genetic predispositions associated with diseases like Parkinson's, Huntington's disease, and Amyotrophic Lateral Sclerosis, potentially leading to targeted therapies based on individual genetic profiles. Additionally, algorithms can analyze pupillary response data to predict disease severity and progression, with pupil dynamics correlating to disease stages and informing treatment customization. Automated monitoring and real-time feedback capabilities have transformed patient care through continuous disease progression tracking and treatment efficacy assessment. Wearable devices equipped with sensors can collect real-time data on motor function, including tremors and gait patterns in Parkinson's patients, transmitting this information to machine learning models for immediate analysis. These systems provide instant feedback to both patients and healthcare providers, enabling rapid treatment adjustments when necessary. Smartphone applications powered by machine learning utilize motion sensors and voice analysis to track neurological disease progression, with algorithms detecting changes in speech patterns and handwriting that may indicate early motor dysfunction.[25,27].

Neuroinflammation research has benefited significantly from machine learning applications, as inflammation plays a central role in disorders such as Alzheimer's, Parkinson's, and multiple sclerosis. Machine learning models can process complex data from blood biomarkers and immune profiling studies, helping identify inflammatory responses in the brain and immune system. These insights prove valuable for early disease detection and identification of potential therapeutic targets. The integration of machine learning models into clinical workflows has fundamentally improved patient outcomes by enabling healthcare professionals to make more informed decisions while reducing human error. The ability of these systems to identify complex interactions between clinical variables, genetic predispositions, and environmental factors creates opportunities for more comprehensive and effective treatment approaches. This technological advancement represents a significant step toward precision medicine in neurology, where treatment strategies are tailored to individual patient characteristics and disease patterns.[24].

1.10 Disease prevention, diagnosis, and treatment

The comprehensive management of neurological diseases like Alzheimer's and Parkinson's requires a multifaceted approach that spans prevention, diagnosis, and treatment. Each stage of care presents unique opportunities to intervene and improve patient outcomes, with emerging technologies like pupillometry offering new insights across all phases of disease management. Prevention strategies for neurological diseases focus primarily on addressing modifiable risk factors while recognizing that genetic predisposition cannot be changed. For Alzheimer's disease, building cognitive reserve through mentally stimulating activities such as reading, solving puzzles, and maintaining active social interactions may help delay disease onset. Regular aerobic exercise plays a crucial role in reducing Alzheimer's risk by promoting brain health and reducing inflammation. Cardiovascular health maintenance through dietary approaches like the Mediterranean diet, along with controlling hypertension, diabetes, and high cholesterol, can significantly decrease risk. Additionally, proper sleep hygiene is essential, as sleep disturbances and conditions like sleep apnea have been linked to increased amyloid plaque accumulation. Parkinson's disease prevention similarly emphasizes lifestyle modifications, with regular physical activity being particularly important for maintaining motor function. Activities such as tai chi and walking can improve balance and muscle strength, potentially delaying motor symptom onset. Environmental awareness is crucial, as exposure to toxins like pesticides has been associated with increased Parkinson's risk, making toxin avoidance an important preventive measure. Nutritional approaches focusing on antioxidant-rich and anti-inflammatory foods, including green leafy vegetables and berries, may help slow disease progression. Pupillary reflex monitoring is emerging as a valuable prevention tool, as these responses can serve as early indicators of neurological changes, allowing for intervention before more severe symptoms develop.[17].

Diagnostic approaches for Alzheimer's disease rely on multiple assessment methods to build a comprehensive clinical picture. Neuropsychological testing evaluates memory, reasoning, and other cognitive functions, while brain imaging through MRI and PET scans can identify characteristic changes such as hippocampal atrophy and amyloid plaque accumulation. Biomarker analysis of cerebrospinal fluid measures amyloid-beta and tau protein levels, providing direct evidence of Alzheimer's pathology. Increasingly, pupillary light reflex testing and eye tracking are being incorporated into diagnostic protocols, as abnormal pupil dilation and constriction patterns can indicate early neurodegenerative changes with remarkable precision. Parkinson's disease diagnosis centers on clinical motor assessment, with physicians evaluating tremors, rigidity, bradykinesia, and postural instability using standardized tools like the Unified Parkinson's Disease Rating Scale. Specialized imaging such as dopamine transporter scans using SPECT technology can measure the integrity of dopamine-producing brain cells, helping confirm diagnosis. Advanced technologies including voice analysis and movement monitoring through wearable sensors can detect subtle early symptoms in speech and gait patterns. Pupillometry is gaining recognition as a valuable diagnostic tool, as changes in pupillary light reflex, including reduced constriction or delayed response times, can indicate autonomic nervous system dysregulation commonly seen in Parkinson's disease. The diagnostic applications of pupillary responses extend beyond simple reflex testing to sophisticated analysis of pupillary dynamics. Early-stage diseases may manifest through abnormal pupillary light reflexes before other symptoms become apparent, with pupillometry capable of detecting subtle changes such as slower constriction, irregular dilation, or asymmetry between eyes. Advanced machine learning algorithms are increasingly being developed to analyze these pupillary patterns, offering the potential to track disease progression and predict future neurological decline with greater accuracy than traditional methods.[8].

Treatment approaches for Alzheimer's disease currently focus on symptom management and slowing progression, as no cure exists. Cholinesterase inhibitors like Donepezil work by increasing acetylcholine levels in the brain, improving memory and cognitive function. NMDA receptor antagonists such as meantime help regulate glutamate activity and reduce symptoms in moderate to severe disease stages. Newer anti-amyloid treatments, including monoclonal antibodies like Aducanumab, directly target amyloid plaques with the goal of slowing disease progression. Lifestyle modifications including structured routines, cognitive therapies, and maintained physical activity can help slow cognitive decline and improve quality of life. Parkinson's disease treatment relies heavily on dopamine replacement therapy, with Levodopa combined with Carbidopa being the most commonly prescribed medication to replace missing brain dopamine. Dopamine agonists mimic dopamine's effects and can effectively reduce symptoms, particularly in early disease stages. MAO-B inhibitors prevent dopamine breakdown, providing longer-lasting symptom relief. For advanced cases, surgical interventions such as Deep Brain Stimulation can significantly reduce motor symptoms by stimulating specific brain regions. Comprehensive rehabilitation including occupational therapy, physical therapy, and speech therapy helps manage motor symptoms, improve mobility, and maintain quality of life. Pupillometry offers unique advantages in treatment monitoring and optimization. Changes in pupillary responses can provide insights into treatment effectiveness, particularly for interventions like transcranial magnetic stimulation or deep brain stimulation that may directly affect pupillary function. For pharmacological treatments, pupillary dynamics can offer valuable feedback about medication efficacy and potential side effects, especially important for drugs like dopamine agonists that affect autonomic responses. This real-time monitoring capability makes pupillometry an increasingly valuable tool for personalizing treatment approaches and optimizing therapeutic outcomes across various neurological conditions.[34].

Quantum Support Vector Machine

SVM classifies difficult datasets using the ‘‘kernel trick’’, which projects input data points into a high-dimensional space and facilitates the solution to non-linear separable issues. Currently, there are several kernel functions utilized, which can be computationally expensive and inefficient. So Quantum Kernel is used. Quantum kernels use quantum mechanics to improve feature vector mapping. Quantum Kernel-Based Machine Learning, incorporating QSVM, is revolutionizing data analysis and classification. By integrating quantum principles, these innovations unlock unprecedented computational capabilities, outperforming classical methods in various applications.[35]. Quantum kernel machine learning relies on using quantum feature maps to carry out the kernel trick. Here, a quantum feature map transforms a classical feature x into a point in Hilbert space, yielding the quantum kernel. φ(x). It is mathematically illustrated by Eq is

$$K_{ij} = \varphi(\vec{x}_i) \quad \varphi\, \vec{x}_j$$

where Kij is the kernel matrix, φ (x) is the quantum feature map, xi, and xj are n-dimensional inputs, and |⟨a | b⟩|2 denotes the two quantum states, a and b, overlap. [35]



Fig: 1 Block diagram of the QSVM.

The quantum advantage stems from the ability to construct datasets where quantum processing can recognize intrinsic labeling patterns that appear as random noise to classical computers. This capability is particularly relevant for neurological diseases where subtle biomarkers may be embedded in complex, high-dimensional data structures.[35].

The integration of quantum machine learning with ensemble deep learning creates a powerful hybrid framework. This approach combines customized VGG16 and ResNet50 models for feature extraction with Quantum Support Vector Machine (QSVM) classifiers for final classification. The ensemble methodology extracts meaningful features from neuroimaging data using deep learning, then feeds these features to quantum classifiers.

Performance achievements of this hybrid approach include:

- Accuracy: 99.89%
- F1-score: 98.37%
- Superior performance compared to classical ensemble methods

1.12 Quantum Feature Maps and Entanglement

Quantum feature maps play a crucial role in QSVM performance. Research indicates that first-order Pauli maps (X and Z feature maps) provide optimal accuracy for EEG data in neurological applications. The choice of feature map significantly impacts classification performance, with entanglement-heavy maps sometimes performing poorly due to classical simulator limitations. Variational Quantum Circuits (VQCs) used in QSVM frameworks demonstrate runtime complexity of $O(Nt/\varepsilon^2)$, where N is the number of qubits, t is iterations, and ε is the error margin. These circuits achieve over 90% accuracy in distinguishing entangled states despite hardware noise.

Quantum ensemble learning offers unique advantages over classical ensemble methods. Exponentially large ensembles can be created in quantum systems, leveraging quantum parallelism to evaluate multiple models simultaneously. This approach enables:

1. Optimization-free learning by replacing optimization with integration problems
2. Parallel evaluation of ensemble member predictions through quantum superposition
3. Enhanced collective decision-making using quantum interference effects

CONCLUSION

The identification of neurological diseases through machine learning (ML) signifies a groundbreaking development in contemporary medical science, presenting new opportunities for early diagnosis, disease monitoring, and tailored treatment. Neurological conditions such as Alzheimer's disease, Parkinson's disease, epilepsy, and multiple sclerosis have historically presented diagnostic difficulties due to their overlapping clinical manifestations, gradual onset, and the constraints of traditional diagnostic methods. The incorporation of artificial intelligence (AI) and ML into neurology offers a robust alternative that improves diagnostic accuracy, minimizes subjectivity, and speeds up clinical decision-making. In this research, various machine learning and deep learning techniques were examined for their use in identifying neurological disorders. Conventional ML algorithms like Support Vector Machines (SVM), Random Forests (RF), and Logistic Regression have shown strong predictive performance, especially when combined with enhanced feature extraction and selection methods. These models have been effective in processing structured datasets, including clinical and tabular information. On the other hand, deep learning frameworks such as Convolutional Neural Networks (CNNs) and Recurrent Neural Networks (RNNs) have transformed neuroimaging and signal processing by autonomously learning intricate patterns within MRI, CT, and EEG data. Their capacity to identify subtle structural and functional irregularities in the brain has rendered them essential for early disease detection and classification. The effectiveness of ML-based diagnostic systems is significantly influenced by the quality of data collection, thorough preprocessing, and strong model validation. Methods such as normalization, augmentation, and dimensionality reduction help maintain data consistency and mitigate over fitting.

Additionally, assessing performance through metrics like accuracy, precision, recall, specificity, and AUC-ROC offers a detailed insight into model performance. Nonetheless, it is crucial to recognize the ongoing challenges. Issues such as limited data availability, variations in imaging techniques, ethical dilemmas surrounding patient confidentiality, and the opaque nature of deep learning models impede broader clinical implementation. Tackling these challenges with explainable AI (XAI), federated learning, and data-sharing initiatives can enhance trust and transparency in AI-enhanced healthcare. In spite of these obstacles, the future of neurological diagnostics is rooted in the fusion of ML with multimodal and longitudinal datasets. Merging neuroimaging, electrophysiological data, genomic information, and behavioral insights can provide a more comprehensive view of disease evolution and patient treatment responses. AI-driven decision support systems can also aid neurologists in efficiently screening large populations, especially in resource-limited environments where specialist access is scarce. Moreover, integrating Internet of Things (IoT) devices and wearable technology facilitates ongoing patient monitoring, allowing for immediate detection of irregularities and prompt interventions.

REFERENCE

1. Gao, H.-M.; Hong, J.-S. (2008). Why Neurodegenerative Diseases Are Progressive: Uncontrolled Inflammation Drives Disease Progression. *Trends Immunol*, *29*, 357–365.
2. Gupta C, Chandrashekar P, Jin T, et al. Bringing machine learning to research on intellectual and developmental disabilities: Taking inspiration from neurological diseases. J Neurodev Disord. 2022;14:28. https://doi.org/10.1186/s11689-022- 09438-w.

3. Choudhary D, Nasiruddin Khan MD, Khan Z, et al. Navigating the complexities of neuronal signaling and targets in neurological disorders: From pathology to therapeutics. Eur J Pharmacol. 2025; 995:177417. https://doi.org/10.1016/ j.ejphar.2025.177417.
4. Cummings J, Lee G, Zhong K, Fonseca J, Taghva K. Alzheimer's disease drug development pipeline: 2021. Alzheimers Dement (N Y). 2021;7:e12179. https:// doi.org/10.1002/trc2.12179.
5. Huang LK, Chao SP, Hu CJ. Clinical trials of new drugs for Alzheimer disease. J Biomed Sci. 2020; 27:18. https://doi.org/10.1186/s12929-019-0609-7.
6. GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:459–480. https://doi.org/10.1016/ S1474-4422(18)30499-X.
7. Deuschl G, Beghi E, Fazekas F, et al. The burden of neurological diseases in europe: An analysis for the global burden of disease study 2017. Lancet Public Health. 2020;5: e551–e567. https://doi.org/10.1016/S2468-2667 (20)30190-0.
8. Mbizvo GK, Bennett K, Simpson CR, Duncan SE, Chin RFM. Epilepsy-related and other causes of mortality in people with epilepsy: A systematic review of systematic reviews. Epilepsy Res. 2019;157:106192. https://doi.org/10.1016/ j.eplepsyres.2019.106192.
9. Allers K, Essue BM, Hackett ML, et al. The economic impact of epilepsy: A systematic review. BMC Neurol. 2015;15:245. https://doi.org/10.1186/s12883-015-0494-y.
10. Cicirelli, G.; Impedovo, D.; Dentamaro, V.; Marani, R.; Pirlo, G.; D'Orazio, T.R. Human gait analysis in neurodegenerative diseases: A review. *IEEE J. Biomed. Health Inform.* **2021**, *26*, 229–242. [**Google Scholar**] [**CrossRef**]
11. Buckley, C.; Alcock, L.; McArdle, R.; Rehman, R.Z.U.; Del Din, S.; Mazzà, C.; Yarnall, A.J.; Rochester, L. The role of movement analysis in diagnosing and monitoring neurodegenerative conditions: Insights from gait and postural control. *Brain Sci.* **2019**, *9*, 34. [**Google Scholar**] [**CrossRef**]
12. Sciarrone, A.; Bisio, I.; Garibotto, C.; Lavagetto, F.; Staude, G.H.; Knopp, A. Leveraging IoT wearable technology towards early diagnosis of neurological diseases. *IEEE J. Sel. Areas Commun.* **2020**, *39*, 582–592. [**Google Scholar**] [**CrossRef**]
13. Hammoud, M.; Kovalenko, E.; Somov, A.; Bril, E.; Baldycheva, A. Deep learning framework for neurological diseases diagnosis through near-infrared eye video and time series imaging algorithms. *Internet Things* **2023**, *24*, 100914. [**Google Scholar**] [**CrossRef**]
14. Billones, C.D.; Demetria, O.J.L.D.; Hostallero, D.E.D.; Naval, P.C. DemNet: A convolutional neural network for the detection of Alzheimer's disease and mild cognitive impairment. In Proceedings of the 2016 IEEE Region 10 Conference (TENCON), Singapore, 22–25 November 2016; pp. 3724–3727. [**Google Scholar**]
15. Horlings CGC, Rath J, Finsterer J, Wanschitz JV, Loscher WN. Laboratory tests for € neuropathies: What to do and to avoid. J Neuromuscul Dis. 2020;7:279–286. https:// doi.org/10.3233/JND-200488.
16. Paprocka J, Coppola A, Cuccurullo C, Stawicka E, Striano P. Epilepsy, EEG and chromosomal rearrangements. Epilepsia Open. 2024;9:1192–1232. https://doi.org/ 10.1002/epi4.12951.
17. Gorgülü Ü, Ergün U, Ertu € grul L. Peripheral nerve conductions in relapsing remitting multiple sclerosis (RRMS) patients. J Clin Neurosci. 2020;74:93–97. https://doi.org/ 10.1016/j.jocn.2020.01.058.
18. . Kampmann M. CRISPR-based functional genomics for neurological disease. Nat Rev Neurol. 2020;16:465–480. https://doi.org/10.1038/s41582-020-0373-z.
19. Scheijen EEM, Wilson 3rd DM. Genome integrity and neurological disease. Int J Mol Sci. 2022;23:4142. https://doi.org/10.3390/ijms23084142.
20. . Altuna-Azkargorta M, Mendioroz-Iriarte M. Blood biomarkers in Alzheimer's disease. Neurologia. 2021;36:704–710. https://doi.org/10.1016/j.nrleng.2018.03.006.
21. Abdelhak A, Foschi M, Abu-Rumeileh S, et al. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat Rev Neurol. 2022;18:158–172. https:// doi.org/10.1038/s41582-021-00616-3.
22. Abirami, P. C. Chapter Fourteen—Energy-efficient edge based real-time healthcare support system. *Adv. Comput.* 117(1), 339–368 (2020).
23. Jabardi, M., Al-Fatlawi, A. & Ling, H. (2016) Efficient diagnosis system for Parkinson's Disease using deep belief network. In *Conference: 2016 IEEE Congress on Evolutionary Computation (CEC)*. At: Vancouver, Canada. 16468312:1-8.
24. Bilgen, I., Guvercin, G. & Rekik, I. Machine learning methods for brain network classification: Application to autism diagnosis using cortical morphological networks. *J. Neurosci. Methods* 343(1), 1–31 (2020).25
25. Lynch G. Using Pupillometry to Assess the Atypical Pupillary Light Reflex and LC-NE System in ASD. Behav Sci (Basel). 2018 Nov 21;8(11) [PMC free article] [PubMed]

26. Meltzoff AN, Kuhl PK, Movellan J, Sejnowski TJ. Foundations for a new science of learning. Science. 2009;325:284–8. [DOI] [PubMed] [PMC]

27. Mitchell TM. Machine learning. New York: McGraw-Hill; 1997.

28. Murphy KP. Machine learning: a probabilistic perspective. Cambridge: MIT Press; 2012.

29. Kuhn, M., & Johnson, K. (2013). *Applied Predictive Modeling*. Springer. Emphasizes that k-NN and Logistic Regression perform well for small to medium-sized data and binary classification problems.

30. Zhang, Z. (2016). *Introduction to machine learning: k-Nearest Neighbors and Logistic Regression*. Annals of Translational Medicine, 4(11), 218.

31. Ceni, Elisabetta, Tommaso Mello and Andrea Galli. "Pathogenesis of alcoholic liver disease: Role of oxidative metabolism." World J Gastroenterol 20 (2014): 17756.

32. Bosemani, Thangamadhan, Gunes Orman, Eugen Boltshauser and Aylin Tekes, et al. "Congenital abnormalities of the posterior fossa." Radiographics 35 (2015): 200-220.

33. Volonté C. Machine learning as a new tool in neurological disease prevention, diagnosis, and treatment

34. Faust, O., Hagiwara, Y., Hong, T. J., Lih, O. S., & Acharya, U. R. (2018). *Deep learning for healthcare applications based on physiological signals: A review*. Computer Methods and Programs in Biomedicine, 161, 1–13.

35. T. Sinha, M. V. Munot, and R. Sreemathy, ‘‘An efficient approach for detection of autism spectrum disorder using electroencephalography signal,’’ IETE J. Res., vol. 68, no. 2, pp. 824–832, Jun. 2019, doi: 10.1080/03772063.2019.1622462.